Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
High levels of variability in cancer-related cellular signalling networks and a lack of parameter identifiability in large-scale network models hamper translation of the results of modelling studies into the process of anti-cancer drug development. Recently global sensitivity analysis (GSA) has been recognised as a useful technique, capable of addressing the uncertainty of the model parameters and generating valid predictions on parametric sensitivities. Here we propose a novel implementation of model-based GSA specially designed to explore how multi-parametric network perturbations affect signal propagation through cancer-related networks. We use area-under-the-curve for time course of changes in phosphorylation of proteins as a characteristic for sensitivity analysis and rank network parameters with regard to their impact on the level of key cancer-related outputs, separating strong inhibitory from stimulatory effects. This allows interpretation of the results in terms which can incorporate the effects of potential anti-cancer drugs on targets and the associated biological markers of cancer. To illustrate the method we applied it to an ErbB signalling network model and explored the sensitivity profile of its key model readout, phosphorylated Akt, in the absence and presence of the ErbB2 inhibitor pertuzumab. The method successfully identified the parameters associated with elevation or suppression of Akt phosphorylation in the ErbB2/3 network. From analysis and comparison of the sensitivity profiles of pAkt in the absence and presence of targeted drugs we derived predictions of drug targets, cancer-related biomarkers and generated hypotheses for combinatorial therapy. Several key predictions have been confirmed in experiments using human ovarian carcinoma cell lines. We also compared GSA-derived predictions with the results of local sensitivity analysis and discuss the applicability of both methods. We propose that the developed GSA procedure can serve as a refining tool in combinatorial anti-cancer drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A methodology for performing global uncertainty and sensitivity analysis in systems biology
Marino, S., Hogue, I. B., Ray, C. J., & Kirschner, D. E. (2008) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2008.04.011 · Cited by 2,999
A Quantitative Model-Independent Method for Global Sensitivity Analysis of Model Output
Saltelli, A., Tarantola, S., & Chan, K. P.-S. (1999) · Technometrics · doi:10.1080/00401706.1999.10485594 · Cited by 2,275 · cited 1×
“While the general GSA theory has been under development for nearly three decades (Chang and Delleur, 1992; Saltelli et al., 1999), the potential of using GSA for systems biology applications has been recognised only relatively recently.”
The systems biology graphical notation.
Novère, N. L., Hucka, M., Mi, H., Moodie, S., Schreiber, F., Sorokin, A., Demir, E., Wegner, K., Aladjem, M. I., Wimalaratne, S. M., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1558 · Cited by 903 · cited 2×
“General scheme of the ErbB2/3 network model, presented in SBGN notation (Le Novere et al., 2009).”
Self-citationA hybrid approach for efficient and robust parameter estimation in biochemical pathways
Rodriguez-Fernandez, M., Mendes, P., & Banga, J. R. (2006) · Biosystems · doi:10.1016/j.biosystems.2005.06.016 · Cited by 304
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation
Schoeberl, B., Faber, A. C., Li, D., Liang, M.-C., Crosby, K., Onsum, M., Burenkova, O., Pace, E., Walton, Z., Nie, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3145 · Cited by 264 · cited 11×
“The highest sensitivity of S was found for the total amount of ErbB3 and ErbB2, which con-firms that expression level of these receptors plays a significant role in modulating the response of the ErbB network to anti-ErbB2 inhibitors.”
InfluentialHATAKEYAMA, M., KIMURA, S., NAKA, T., KAWASAKI, T., YUMOTO, N., ICHIKAWA, M., KIM, J.-H., SAITO, K., SAEKI, M., SHIROUZU, M., et al. (2003) · Biochemical Journal · doi:10.1042/bj20021824 · Cited by 233
An iterative identification procedure for dynamic modeling of biochemical networks
Balsa-Canto, E., Alonso, A. A., & Banga, J. R. (2010) · BMC Systems Biology · doi:10.1186/1752-0509-4-11 · Cited by 202
Comparative study of parameter sensitivity analyses of the TCR-activated Erk-MAPK signalling pathway
Zheng, Y., & Rundell, A. (2006) · IEE Proceedings - Systems Biology · doi:10.1049/ip-syb:20050088 · Cited by 121 · cited 4×
“Although examples of the application of GSA to biochemical network models are still rare, they have already shown promise for understanding the effects of multiparametric perturbations on biologically meaningful model outputs (Jia et al., 2007; Kim et al., 2010; Marino et al., 2008; Yoon and Deisboeck, 2009; Zheng and…”
Influential
Cited by
Zhang, X., Trame, M., Lesko, L., & Schmidt, S. (2015) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.6 · Cited by 467
“Similar to other target identification studies, the area between baseline and effect curve was used as the model output for determining the changes in pAkt over time.(11,21,51) As shown in our previous work, there were seven important parameters and steps associated with pAkt inhibition by sunitinib.”
MethodGlobal sensitivity analysis of biological multiscale models
Renardy, M., Hult, C., Evans, S., Linderman, J. J., & Kirschner, D. E. (2019) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2019.09.012 · Cited by 63
Zhang, X., Birtwistle, M., & Gallo, J. (2014) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.65 · Cited by 33
RKappa: Software for Analyzing Rule-Based Models
Sorokin, A., Sorokina, O., & Douglas Armstrong, J. (2019) · Methods in Molecular Biology · doi:10.1007/978-1-4939-9102-0_17 · Cited by 4
Self-citation
Metadata
- Authors
- Lebedeva, G., Sorokin, A., Faratian, D., Mullen, P., Goltsov, A., Langdon, S. P., Harrison, D. J., & Goryanin, I.
- Venue
- European Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 2012-07
- Volume
- 46
- Issue
- 4
- Pages
- 244-258
- ISSN
- 0928-0987 (ISSN-L)
- OpenAlex
- W2069103780
- Cited by
- 39
- References
- 8
- FWCI
- 1.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.